EFNS guidelines on pharmacological treatment of neuropathic pain

@article{Attal2006EFNSGO,
  title={EFNS guidelines on pharmacological treatment of neuropathic pain},
  author={Nadine Attal and Giorgio Cruccu and Maija L Haanp{\"a}{\"a} and Per T. Hansson and Troels Staehelin Jensen and Turo Nurmikko and Cristina Sampaio and S{\o}ren H. Sindrup and Philip J Wiffen},
  journal={European Journal of Neurology},
  year={2006},
  volume={13}
}
Neuropathic pain treatment remains unsatisfactory despite a substantial increase in the number of trials. [...] Key Method Studies were identified using first the Cochrane Database then Medline. Trials were classified according to the aetiological condition. All class I and II controlled trials (according to EFNS classification of evidence) were assessed, but lower-class studies were considered in conditions that had no top level studies. Only treatments feasible in an outpatient setting were evaluated. Effects…Expand
Treatment of neuropathic pain: an overview of recent guidelines.
TLDR
Evidence-based guidelines for the pharmacologic management of neuropathic pain that take into account clinical efficacy, adverse effects, impact on health-related quality of life, convenience, and costs are developed. Expand
Algorithm for neuropathic pain treatment : An evidence based proposal
New studies of the treatment of neuropathic pain have increased the need for an updated review of randomized, double-blind, placebocontrolled trials to support an evidence based algorithm to treatExpand
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
TLDR
The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of several recent clinical trials. Expand
Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society.
TLDR
Randomized, controlled trials, systematic reviews and existing guidelines focusing on the pharmacological management of NeP were evaluated at a consensus meeting and recommendations for treatment are based on degree of evidence of analgesic efficacy, safety, ease of use and cost-effectiveness. Expand
Pharmacologic management of neuropathic pain: Evidence-based recommendations
TLDR
Patients with neuropathic pain are challenging to manage and evidence‐based clinical recommendations for pharmacologic management are needed, and medications should be individualized, considering side effects, potential beneficial or deleterious effects on comorbidities, and whether prompt onset of pain relief is necessary. Expand
Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?
TLDR
Improving the current way of conducting clinical trials in NP could contribute to reduce therapeutic failures and may have an impact on future therapeutic algorithms. Expand
Toward a definition of pharmacoresistant neuropathic pain
TLDR
At present there is devoid of detailed information on mechanisms of spontaneous and stimulus-evoked neuropathic pain which offsets a mechanism based treatment approach with available drugs and strategies on how to identify responders/ non-responders are lacking. Expand
Review and recommendations Pharmacologic management of neuropathic pain: Evidence-based recommendations
TLDR
Systematic literature reviews, randomized clinical trials, and existing guidelines were evaluated at a consensus meeting and recommended first-line treatments include certain antidepressants, gabapentin and pregabalin, and topical lidocaine. Expand
Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process
TLDR
Combination of pregabalin/gabapentin with TCA is useful in patients who do not gain sufficient pain relief or tolerate either drug in high doses, or to improve sleep disturbance, and the evidence for combining TCAs and SNRIs is insufficient, although sometimes used in clinical practice despite the risk of serotonin syndrome. Expand
Management of neuropathic pain
TLDR
For each patient, considerations on the underlying pain mechanisms, immediate and potential long-term side effects, and price as well as comorbidities and concurrent medications will decide which drug should be the first choice, but until further progress is made towards a mechanism-based classification, treatment is likely to be a trial-and-error process where drug combinations may also be considered. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 210 REFERENCES
Chronic Neuropathic Pain: Mechanisms and Treatment
  • N. Attal
  • Medicine
  • The Clinical journal of pain
  • 2000
TLDR
A mechanism‐based approach seems promising for clinical research studies, although its application in current management remains challenging. Expand
Algorithm for neuropathic pain treatment : An evidence based proposal
New studies of the treatment of neuropathic pain have increased the need for an updated review of randomized, double-blind, placebocontrolled trials to support an evidence based algorithm to treatExpand
EFNS guidelines on neuropathic pain assessment
TLDR
This review led to the development of guidelines to be used in the management of patients with neuropathic pain, and the simplest psychometric scales and quality of life measures are probably the best methods. Expand
Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions
TLDR
Doses of riluzole at (100 mg or above) those used for the treatment of ALS were not effective in alleviating peripheral neuropathic pain. Expand
A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes
TLDR
A meta‐analysis of the controlled clinical trial data for peripheral neuropathic pain (PNP) and complex regional pain syndromes (CRPS) indicated that mexiletine and intravenous morphine were probably effective analgesics for PNP, while non‐steroidals were probably ineffective. Expand
Antidepressants for neuropathic pain.
TLDR
This update has provided additional confirmation on the effectiveness of antidepressants for neuropathic pain and has provided new information on another antidepressant - venlafaxine. Expand
Carbamazepine for acute and chronic pain.
TLDR
To evaluate the analgesic effectiveness and adverse effects of the anticonvulsant medicine carbamazepine for pain management in clinical practice and to identify a clinical research agenda, randomised trials of anticonVulsants in acute, chronic or cancer pain were evaluated. Expand
Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action
TLDR
It is concluded that tricyclic antidepressants in optimal doses appear to be the most efficient treatment of neuropathic pain, but some of the other treatments may be important due to their better tolerability. Expand
Oral opioid therapy for chronic peripheral and central neuropathic pain.
TLDR
The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses, and higher doses produced more side effects without significant additional benefit in terms of other outcome measures. Expand
Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review
TLDR
The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and gabapentinoids in PHN, and a single study of spinal intrathecal administration of lidocaine and methylprednisolone demonstrated efficacy, although this has yet to be replicated. Expand
...
1
2
3
4
5
...